{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:36:41Z","timestamp":1770532601409,"version":"3.49.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtct.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:36:55Z","timestamp":1729078615000},"page":"34.e1-34.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto\/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-6864","authenticated-orcid":false,"given":"Jean","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-0164","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1289-8968","authenticated-orcid":false,"given":"Valentyn","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafik","family":"Terra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Caudrelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7950-9354","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Thiant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9286-3798","authenticated-orcid":false,"given":"Gabrielle","family":"Thauvette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bambace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1692","authenticated-orcid":false,"given":"Denis Claude","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-1769","authenticated-orcid":false,"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.10.008_bib0001","unstructured":"National Cancer institute. Cancer Stat Facts: Myeloma [Internet]. 2023. Available from https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed October 24, 2024."},{"key":"10.1016\/j.jtct.2024.10.008_bib0002","doi-asserted-by":"crossref","unstructured":"Goel U, Usmani S, Kumar S Current approaches to management of newly diagnosed multiple myeloma. American J Hematol [Internet]. 2022;97(S1). Available from https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26512. Accessed October 24, 2024.","DOI":"10.1002\/ajh.26512"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0003","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2024.10.008_bib0004","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2024.10.008_bib0005","doi-asserted-by":"crossref","first-page":"e14099","DOI":"10.1111\/ctr.14099","article-title":"Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only","volume":"34","author":"LeBlanc","year":"2020","journal-title":"Clin Transplantation"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.2018.200253","article-title":"Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma","volume":"104","author":"Maffini","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.008_bib0007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2015.319","article-title":"Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation","volume":"51","author":"Ahmad","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0008","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"9023","key":"10.1016\/j.jtct.2024.10.008_bib0009","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect","volume":"348","author":"Aschan","year":"1996","journal-title":"The Lancet"},{"issue":"18","key":"10.1016\/j.jtct.2024.10.008_bib0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0011","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.jtct.2024.10.008_bib0012","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bmt.1705393","article-title":"Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"37","author":"Van De Donk","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0013","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kr\u00f6ger","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.008_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2141.2003.04237.x","article-title":"Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation","volume":"121","author":"P\u00e9rez-Sim\u00f3n","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0016","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous\u2013allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kr\u00f6ger","year":"2013","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0018","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.008_bib0019","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/jcm9072180","article-title":"Allogeneic transplantation in multiple myeloma\u2014does it still have a place?","volume":"9","author":"Gahrton","year":"2020","journal-title":"JCM"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.008_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-6-2","article-title":"Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Kharfan-Dabaja","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.008_bib0021","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bbmt.2015.04.020","article-title":"Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"21","author":"Beaussant","year":"2015","journal-title":"Biol Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.008_bib0022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13014-022-02161-9","article-title":"Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation","volume":"17","author":"Gruber","year":"2022","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.008_bib0023","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2019.05.016","article-title":"Resolved versus active chronic graft-versus-host disease: impact on post-transplantation quality of life","volume":"25","author":"Kurosawa","year":"2019","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.008_bib0024","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.008_bib0025","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2024.10.008_bib0026","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2024.10.008_bib0027","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.008_bib0028","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbmt.2015.02.015","article-title":"Cord blood transplantation for multiple myeloma: a study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"21","author":"Kawamura","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.008_bib0029","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3324\/haematol.2015.138917","article-title":"Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT","volume":"101","author":"Paviglianiti","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.008_bib0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","article-title":"Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation","volume":"27","author":"Olson","year":"2021","journal-title":"Transplantation Cellular Therapy"},{"issue":"13","key":"10.1016\/j.jtct.2024.10.008_bib0031","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood-2007-05-092130","article-title":"Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing","volume":"110","author":"Komanduri","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14653240701231014","article-title":"Immune reconstitution after unrelated cord blood transplantation","volume":"9","author":"Szabolcs","year":"2007","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1016\/j.jtct.2024.10.008_bib0033","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa041276","article-title":"Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia","volume":"351","author":"Laughlin","year":"2004","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jtct.2024.10.008_bib0034","first-page":"2204","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0035","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/bloodadvances.2022009253","article-title":"T-cell replete cord transplants give superior outcomes in high-risk and relapsed\/refractory pediatric myeloid malignancy","volume":"7","author":"Horgan","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"10.1016\/j.jtct.2024.10.008_bib0036","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1002\/sctm.20-0495","article-title":"Umbilical cord blood transplantation: Still growing and improving","volume":"10","author":"Zhu","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0037","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clim.2008.02.008","article-title":"Umbilical cord blood transplantation: Basic biology and clinical challenges to immune reconstitution","volume":"127","author":"Brown","year":"2008","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.09.031","article-title":"UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections","volume":"27","author":"Dumont-Lagac\u00e9","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0039","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2020001793","article-title":"Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality","volume":"4","author":"Ustun","year":"2020","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0040","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bbmt.2018.11.029","article-title":"Flt3L treatment of bone marrow donors increases graft plasmacytoid dendritic cell content and improves allogeneic transplantation outcomes","volume":"25","author":"Hassan","year":"2019","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0041","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/S2352-3026(19)30202-9","article-title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1\u20132 safety and feasibility study","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0042","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0043","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.008_bib0044","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J Natl Cancer Institute"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.008_bib0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.008_bib0046","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0047","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group Report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0048","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.008_bib0049","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"JCO."},{"issue":"8","key":"10.1016\/j.jtct.2024.10.008_bib0050","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.10.008_bib0051","unstructured":"Available from www.cibmtr.org. Accessed October 24, 2024."},{"issue":"10","key":"10.1016\/j.jtct.2024.10.008_bib0052","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1182\/blood.V88.10.4058.bloodjournal88104058","article-title":"Mortality hazard functions as related to neutropenia at different times after marrow transplantation","volume":"88","author":"Offner","year":"1996","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2024.10.008_bib0053","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1182\/blood-2011-01-283606","article-title":"Ex vivo expansion of human hematopoietic stem and progenitor cells","volume":"117","author":"Dahlberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.008_bib0054","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jtct.2022.11.007","article-title":"Clinical outcomes of umbilical cord blood transplantation using ex vivo expansion: a systematic review and meta-analysis of controlled studies","volume":"29","author":"Saiyin","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0056","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V88.3.795.795","article-title":"Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease","volume":"88","author":"Wagner","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0057","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/bmt.2016.265","article-title":"GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes","volume":"52","author":"Chen","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.10.008_bib0058","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2008-07-163238","article-title":"Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors","volume":"113","author":"MacMillan","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2024.10.008_bib0059","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1182\/blood-2013-08-519157","article-title":"Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells","volume":"122","author":"Leveson-Gower","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/bmt.2012.117","article-title":"Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle-Therapie Cellulaire collaborative study","volume":"48","author":"Dumas","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.008_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.903063","article-title":"Epstein-Barr virus reactivation after paediatric haematopoietic stem cell transplantation: risk factors and sensitivity analysis of mathematical model","volume":"13","author":"Kania","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.008_bib0062","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/vaccines9030288","article-title":"Factors associated with post-transplant active epstein-barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"9","author":"Enok Bonong","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.008_bib0063","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/curroncol31050211","article-title":"Epstein\u2013Barr virus monitoring after an allogeneic hematopoietic stem cell transplant: review of the recent data and current practices in Canada","volume":"31","author":"Ratiu","year":"2024","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.008_bib0064","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/bmt.2011.64","article-title":"Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation","volume":"47","author":"Peric","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.008_bib0066","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clml.2021.12.015","article-title":"Clinical characteristics of posttransplant lymphoproliferative disorder after cord blood transplantation without antithymocyte globulin","volume":"22","author":"Sumi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.008_bib0067","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","article-title":"Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation","volume":"25","author":"Fujimoto","year":"2019","journal-title":"Biol Blood Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0068","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","article-title":"Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs","volume":"43","author":"Parlakpinar","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.008_bib0069","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41409-021-01532-2","article-title":"Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous\/allogeneic transplant followed by bortezomib maintenance: a phase II study","volume":"57","author":"LeBlanc","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.008_bib0070","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00277-021-04514-y","article-title":"Long-term outcome after allogeneic stem cell transplantation in multiple myeloma","volume":"100","author":"Luoma","year":"2021","journal-title":"Ann Hematol"},{"issue":"20","key":"10.1016\/j.jtct.2024.10.008_bib0071","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2024.10.008_bib0072","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"23","key":"10.1016\/j.jtct.2024.10.008_bib0073","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"JCO."},{"issue":"1","key":"10.1016\/j.jtct.2024.10.008_bib0074","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"JCO."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:51:48Z","timestamp":1736812308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724007243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666636724007243"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto\/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}